Sharps Technology, Inc. — Form 10-Q Summary
Filing identity: The request identifies Skyai, Inc., but the supplied filing is for Sharps Technology, Inc. (Nasdaq: STSS; warrants: STSSW). This summary reflects the filing provided, for the quarter ended September 30, 2023, filed November 14, 2023.
Business context and reporting period
Sharps is a pre-revenue medical-device company developing and seeking to commercialize safety syringes. It reported no revenue in the three- or nine-month periods ended September 30, 2023, or in the comparable 2022 periods. The company has incurred operating losses since inception and is building inventory and manufacturing capacity in preparation for commercialization.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $2.36 million | $1.80 million | $7.21 million | $5.92 million |
| Net loss | $2.02 million | $2.40 million | $6.74 million | $3.79 million |
| Basic and diluted loss per share | $0.17 | $0.26 | $0.59 | $0.49 |
| Operating cash used | Not provided separately | Not provided separately | $6.14 million | $4.39 million |
Gross margin and operating margin are not meaningful because the company reported no revenue. Q3 other income included a $321,981 gain from fair-value changes in warrant liabilities; the comparable 2022 quarter included a $635,283 loss. For the nine months, the warrant-related fair-value gain was $415,958 in 2023 versus $3.44 million in 2022. These non-cash valuation changes affect reported results.
At September 30, 2023, cash was $5.55 million, working capital was $3.35 million, total assets were $14.37 million, and total liabilities were $3.78 million. Current liabilities were $3.58 million, including a $2.18 million warrant liability. The balance sheet reported no note payable; the prior $2.0 million note was repaid in 2022. Stockholders’ equity was $10.60 million and accumulated deficit was $22.05 million. Cash increased $1.38 million from year-end 2022, reflecting $8.03 million of financing cash inflows offset principally by operating and investing cash use.
Material changes versus comparable periods
- For Q3, net loss narrowed by about $376,000 versus 2022, despite higher total operating expenses. R&D expense fell $232,000 to $225,000, while general and administrative expense rose $794,000 to $2.13 million.
- For the first nine months, net loss increased $2.95 million to $6.74 million. G&A rose $2.02 million to $6.43 million, while R&D fell $738,000 to $783,000. Lower interest expense/income effects and a smaller warrant fair-value gain than in 2022 also affected the comparison.
- Inventory increased to $1.29 million from $186,000 at December 31, 2022, primarily reflecting increased finished goods. Net cash used in operating activities rose by $1.75 million year over year.
- Two September equity offerings raised approximately $5.6 million gross and about $4.9 million net, with issuance of common shares and warrants. Common shares outstanding increased to 15,274,457 by September 30, from 9,407,415 at year-end 2022. The filing also reports 22,815,155 options and warrants excluded from diluted EPS as anti-dilutive.
Outlook, management commentary, risks and unusual items
- Going concern: Management states that working capital is not expected to fund planned operations for the next 12 months and identifies substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on raising financing, including equity or other funding.
- Nephron transaction: In September 2023, Sharps agreed to acquire certain InjectEZ facility equipment and leasehold improvements for $40.38 million cash plus a $10.0 million, five-year subordinated note bearing 8% interest, and to issue warrants representing 4% of fully diluted common stock. Closing depends on obtaining funding for the acquisition and production. The agreement had not closed as of the filing date.
- Customer purchase agreement: Nephron agreed to be the exclusive purchaser of Sharps’ specified pre-filled COC syringes for ten years, with a stated minimum aggregate purchase commitment of $450 million and an initial $32 million order upon closing of the asset purchase. The purchase agreement’s effectiveness is subject to that closing; the filing does not establish that these amounts have been realized as revenue.
- Commercialization: Management describes Securegard as the expected initial commercial product platform. Provensa commercialization has been delayed while the company works to optimize final assembly. The filing gives no revenue guidance or firm commercialization timetable.
- Financing and dilution: September offerings included warrants to buy 8.75 million shares at $0.64 per share, in addition to other outstanding warrants and options. The filing reports $2.18 million of warrant liabilities, remeasured at fair value, with changes flowing through earnings.
- Other items: The company recorded a $375,000 contract-settlement expense in Q2 2023 and accrued about $346,000 in severance and approximately $29,000 for continuing medical benefits under a former executive’s separation agreement. At September 30, about $298,000 remained due to that former executive. No material litigation or other loss contingencies were reported. Management said disclosure controls were effective and reported no material changes in internal control over financial reporting.
Important facts for investors to verify
- Confirm the filing entity: the supplied 10-Q is for Sharps Technology, Inc., not Skyai, Inc.
- Check whether Sharps obtained the financing required to close the InjectEZ asset purchase and fund production, and whether the transaction and Nephron purchase agreement became effective.
- Assess the timing and execution of product commercialization, including Securegard readiness and the Provensa assembly delay.
- Review the company’s cash burn and financing needs against its going-concern warning and stated 12-month funding shortfall.
- Evaluate potential dilution from outstanding warrants, pre-funded warrants and options, including the September PIPE warrants and their liability accounting.